期刊
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
卷 33, 期 3, 页码 323-332出版社
WILEY
DOI: 10.1111/j.1365-2036.2010.04517.x
关键词
-
资金
- Waksman foundation of Japan Inc. [07-2]
P>Background Proton pump inhibitors (PPIs) are less effective in non-erosive reflux disease (NERD) patients than in reflux oesophagitis patients. Whether the addition of prokinetics to PPIs improves NERD patients' symptoms remains unknown. Aim To evaluate the efficacy of mosapride in NERD patients when used with PPI. Methods A total of 200 NERD patients were randomised to one of two arms: omeprazole (10 mg once daily) plus mosapride citrate (5 mg three times a day) (treatment arm) and omeprazole plus placebo (placebo arm). The primary endpoint was the rate of responders [visual analogue scale (VAS) was zero or < 1 cm] after 4 weeks of treatment. The secondary endpoints were changes in the VAS score and the safety profile. Results There was no significant difference between the rates of responders in both arms in intent-to-treat (ITT) and per-protocol (PP) analysis. The change in the VAS score in treatment arm was significantly better than placebo arm in PP analysis (-4.0 +/- 0.2 and -3.3 +/- 0.2, mean +/- S.E.M.) (N.S. in ITT analysis). The rate of adverse events was similar in both groups. Conclusion The addition of mosapride to omeprazole was not more effective than omeprazole alone.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据